Oxford Bioscience Partners - Boston, MA
|
Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. Experienced partners, who bring together deep domain knowledge in life sciences, have established a proven track record of identifying, validating and backing emerging trends and technologies. While willing to consider an investment in a company at almost any stage, OBP brings unique value and expertise to early-stage situations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide, and has successfully leveraged the extensive research, operating, and financial expertise and experience of its team of investment professionals.
Oxford's team of investment professionals has a history of backing leading life science companies, including: SIRNA (acquired by Merck); SOLEXA (acquired by Illumina); ALANTOS (acquired by Amgen); TRUBION (NASDAQ: TRBN); HYPNION (acquired by Eli Lilly); HUMAN GENOME SCIENCES (NASDAQ: HGSI); POWDERMED (acquired by Pfizer); ACADIA (NASDAQ; ACAD); PVT (acquired by Edwards); EXELIXIS (NASDAQ: EXEL); SOSEI (Nikkei: 4565); COHESIVE (acquired by Thermo Fisher); IMPELLA (acquired by Abiomed); STRATAGENE (acquired by Agilent); SANTHERA (SWX:SANN); EXONHIT (EURONEXT: ALEHT); INVERNESS MEDICAL (NYSE: IMA)
|
| |
|
|
 |
|
|
 |
|
October 21, 2009
Advisory Board Meetings
@ Oxford Bioscience Partners
222 Berkeley Street, Suite 1650
Boston, MA 02116
October 22, 2009
Annual Limited Partners Meeting
@ Four Seasons Hotel
200 Boylston Street
Boston, MA 02116
February 2, 2009
New England VCs Well Down Midas List—Oxford’s Fambrough Leads Pack
September 19, 2007
Oxford Bioscience Partners Promotes Dr. Douglas Fambrough to General Partner
July 6, 2007
Oxford Bioscience Keeps Successes on the QT
June 26, 2009
Santhera Enters Agreement with Columbia University to Investigate Additional Potential of Catena® in MELAS --
moreJune 24, 2009
Santhera and NIH Collaborate To Evaluate Catena® in Primary Progressive Multiple Sclerosis --
moreJune 22, 2009
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration --
moreJune 1, 2009
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) --
moreMay 29, 2009
AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer --
moreMay 27, 2009
ExonHit and Institut Gustave Roussy Announce the Signing of a License Agreement for Novel Breast Cancer Diagnostic Assay --
moreMay 21, 2009
Pathway Medical Technologies Closes $42.5M Series D Financing; Announces New Investment From WRF --
moreMay 20, 2009
Ceres Yield Results: Energy Crop Benefits are Greatly Underestimated --
more
|
|
|
|